{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T21:12:07Z","timestamp":1773868327173,"version":"3.50.1"},"reference-count":80,"publisher":"Informa UK Limited","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatric Hematology and Oncology"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.3109\/08880018.2013.783891","type":"journal-article","created":{"date-parts":[[2013,8,13]],"date-time":"2013-08-13T14:15:44Z","timestamp":1376403344000},"page":"465-483","source":"Crossref","is-referenced-by-count":29,"title":["Mature B-Cell Lymphoma and Leukemia in Children and Adolescents\u2014Review of Standard Chemotherapy Regimen and Perspectives"],"prefix":"10.3109","volume":"30","author":[{"given":"Jennifer","family":"Worch","sequence":"first","affiliation":[{"name":"1Department of Pediatric Hematology and Oncology, NHL-BFM Study Center, University Children's Hospital, M\u00fcnster, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marius","family":"Rohde","sequence":"additional","affiliation":[{"name":"2Department of Pediatric Hematology and Oncology, NHL-BFM Study Center and University Children's Hospital, Giessen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Birgit","family":"Burkhardt","sequence":"additional","affiliation":[{"name":"1Department of Pediatric Hematology and Oncology, NHL-BFM Study Center, University Children's Hospital, M\u00fcnster, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2013,4,9]]},"reference":[{"key":"e_1_3_1_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation.V2007.1.285.0010285"},{"key":"e_1_3_1_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05735.x"},{"key":"e_1_3_1_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199605093341906"},{"key":"e_1_3_1_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-008-0024-8"},{"key":"e_1_3_1_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2011.09024.x"},{"key":"e_1_3_1_7_1","article-title":"C.O.G.N.-H.L.C. on behalf of the, Children's Oncology Group's 2013 blueprint for research: non-Hodgkin lymphoma","author":"Bollard CM","year":"2012","unstructured":"Bollard CM, Lim MS, Gross TG. C.O.G.N.-H.L.C. on behalf of the, Children's Oncology Group's 2013 blueprint for research: non-Hodgkin lymphoma. Pediatr Blood Cancer. 2012; doi: 10.1002\/pbc.24416.","journal-title":"Pediatr Blood Cancer"},{"key":"e_1_3_1_8_1","unstructured":"World Health Organisation. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue. Lyon:IARC; 2008."},{"key":"e_1_3_1_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403254"},{"key":"e_1_3_1_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature11378"},{"key":"e_1_3_1_11_1","first-page":"1316","article-title":"Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing","author":"Richter J","year":"2012","unstructured":"Richter J, Schlesner M, Hoffmann S, Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing. Nat Genet. 2012;44:1316\u20131320.","journal-title":"Nat Genet"},{"key":"e_1_3_1_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2468"},{"key":"e_1_3_1_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2476"},{"key":"e_1_3_1_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa012914"},{"key":"e_1_3_1_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-10-4213"},{"key":"e_1_3_1_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.21619"},{"key":"e_1_3_1_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-05-349662"},{"key":"e_1_3_1_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-01-330795"},{"key":"e_1_3_1_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-388470"},{"key":"e_1_3_1_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2007.1.297"},{"key":"e_1_3_1_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.06988.x"},{"key":"e_1_3_1_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.11.0700"},{"key":"e_1_3_1_23_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-1161"},{"key":"e_1_3_1_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.11.3370"},{"key":"e_1_3_1_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-07-036673"},{"key":"e_1_3_1_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20382"},{"key":"e_1_3_1_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.245"},{"key":"e_1_3_1_28_1","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1200\/JCO.2010.33.3369","article-title":"Advanced stage, increased lactate dehydrogenase, and primary site, but not adolescent age (>\/ = 15 years), are associated with an increased risk of treatment failure in children and adolescents with mature B-cell non-Hodgkin's lymphoma: results of the FAB LMB 96 study","author":"Cairo MS","year":"2012","unstructured":"Cairo MS, Sposto R, Gerrard M, Advanced stage, increased lactate dehydrogenase, and primary site, but not adolescent age (>\/ = 15 years), are associated with an increased risk of treatment failure in children and adolescents with mature B-cell non-Hodgkin's lymphoma: results of the FAB LMB 96 study. J Clin Oncol. 2012;30:387\u2013393.","journal-title":"J Clin Oncol"},{"key":"e_1_3_1_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.312"},{"key":"e_1_3_1_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07967.x"},{"key":"e_1_3_1_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402828"},{"key":"e_1_3_1_32_1","first-page":"818","article-title":"Combined polymerase chain reaction methods to detect c-myc\/IgH rearrangement in childhood Burkitt's lymphoma for minimal residual disease analysis","author":"Busch K","year":"2004","unstructured":"Busch K, Borkhardt A, Wossmann W, Combined polymerase chain reaction methods to detect c-myc\/IgH rearrangement in childhood Burkitt's lymphoma for minimal residual disease analysis. Haematologica. 2004;89:818\u2013825.","journal-title":"Haematologica"},{"key":"e_1_3_1_33_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.11.3159"},{"key":"e_1_3_1_34_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.8161"},{"key":"e_1_3_1_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2011.08681.x"},{"key":"e_1_3_1_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07144.x"},{"key":"e_1_3_1_37_1","first-page":"948","article-title":"The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95","author":"Woessmann W","year":"2005","unstructured":"Woessmann W, Seidemann K, Mann G, The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95. Blood. 2005;105:948\u2013958.","journal-title":"Blood"},{"key":"e_1_3_1_38_1","first-page":"3294","article-title":"Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: a report of the Berlin-Frankfurt-Munster Group Trial NHL-BFM 90","author":"Reiter A","year":"1999","unstructured":"Reiter A, Schrappe M, Tiemann M, Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: a report of the Berlin-Frankfurt-Munster Group Trial NHL-BFM 90. Blood. 1999;94:3294\u20133306.","journal-title":"Blood"},{"key":"e_1_3_1_39_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2010.537794"},{"key":"e_1_3_1_40_1","article-title":"Treatment and prognosis of childhood and adolescent B-NHL: LMB and BFM perspective","author":"Patte C","year":"2012","unstructured":"Patte C. Treatment and prognosis of childhood and adolescent B-NHL: LMB and BFM perspective. Br J Haematol. 2012;159(Suppl 1):2, Abstract 4.","journal-title":"Br J Haematol"},{"key":"e_1_3_1_41_1","article-title":"In childhood B-cell non Hodgkin's lymphoma (B-NHL) and mature B-cell acute leukemia (B-AL) with CNS disease at diagnosis, patients with blasts in CSF are at higher risk of event","author":"Minard V","year":"2012","unstructured":"Minard V, Auperin A, Leverger G, In childhood B-cell non Hodgkin's lymphoma (B-NHL) and mature B-cell acute leukemia (B-AL) with CNS disease at diagnosis, patients with blasts in CSF are at higher risk of event. Br J Haematol. 2012;159(Suppl 1):43, Abstract 77.","journal-title":"Br J Haematol"},{"key":"e_1_3_1_42_1","article-title":"Similar results are currently observed in the LMB and BFM studies for B-cell Non-Hodgkin's lymphoma and B-AL allowing future common studies","author":"Patte C","unstructured":"Patte C, Zimmermann M, Auperin A, Reiter A. Similar results are currently observed in the LMB and BFM studies for B-cell Non-Hodgkin's lymphoma and B-AL allowing future common studies. Pediatr Blood Cancer 2010;55:795, Abstract O043.","journal-title":"Pediatr Blood Cancer"},{"key":"e_1_3_1_43_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0b013e31826226b1"},{"key":"e_1_3_1_44_1","doi-asserted-by":"publisher","DOI":"10.3109\/08880018.2011.652342"},{"key":"e_1_3_1_45_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.22905"},{"key":"e_1_3_1_46_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.21144"},{"key":"e_1_3_1_47_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.21046"},{"key":"e_1_3_1_48_1","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-200407000-00014"},{"key":"e_1_3_1_49_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.20116"},{"key":"e_1_3_1_50_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2010.030809"},{"key":"e_1_3_1_51_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V114.22.106.106"},{"key":"e_1_3_1_52_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.08.151"},{"key":"e_1_3_1_53_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-04-422709"},{"key":"e_1_3_1_54_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.013177"},{"key":"e_1_3_1_55_1","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0b013e31826b9b57"},{"key":"e_1_3_1_56_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.23110"},{"key":"e_1_3_1_57_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.23152"},{"key":"e_1_3_1_58_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/11.suppl_1.S141"},{"key":"e_1_3_1_59_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2011.08863.x"},{"key":"e_1_3_1_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpag.2012.09.003"},{"key":"e_1_3_1_61_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0b013e3182804d59"},{"key":"e_1_3_1_62_1","doi-asserted-by":"publisher","DOI":"10.1136\/adc.76.4.330"},{"key":"e_1_3_1_63_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32823ecf5b"},{"key":"e_1_3_1_64_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0b013e3182667bc7"},{"key":"e_1_3_1_65_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.677534"},{"key":"e_1_3_1_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2009.09.021"},{"key":"e_1_3_1_67_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.21585"},{"key":"e_1_3_1_68_1","article-title":"Re-induction approaches to relapsed\/refractory childhood and adolescent non Hodgkin\u00a2s lymphoma: BFM perspective","author":"Woessmann W","year":"2012","unstructured":"Woessmann W, Reiter A. Re-induction approaches to relapsed\/refractory childhood and adolescent non Hodgkin\u00a2s lymphoma: BFM perspective. Br J Haematol. 2012;159:Abstract 71.","journal-title":"Br J Haematol"},{"key":"e_1_3_1_69_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-03-1110"},{"key":"e_1_3_1_70_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-1292"},{"key":"e_1_3_1_71_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.6791"},{"key":"e_1_3_1_72_1","article-title":"Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin's lymphoma and Burkitt leukemia: dose-escalation does not increase the response rate","author":"Lisfeld J","year":"2012","unstructured":"Lisfeld J. Burkhardt B, Meinhardt A, Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin's lymphoma and Burkitt leukemia: dose-escalation does not increase the response rate. Br J Haematol. 2012;159(Suppl 1):3, Abstract 6.","journal-title":"Br J Haematol"},{"key":"e_1_3_1_73_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2010.28.15_suppl.9536"},{"key":"e_1_3_1_74_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2012.30.15_suppl.9501"},{"key":"e_1_3_1_75_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08143.x"},{"key":"e_1_3_1_76_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.104.104","article-title":"Preliminary results of the addition of rasburicase to the reduction cycle and rituximab to the induction and consolidation cycles of FAB group C chemotherapy in children and adolescents with advanced stage (Bone Marrow \u00b1CNS) mature B-cell non-hodgkin lymphoma (B-NHL): a children's oncology group report","author":"Goldman S","year":"2009","unstructured":"Goldman S, Lynch J, Harrison L, Preliminary results of the addition of rasburicase to the reduction cycle and rituximab to the induction and consolidation cycles of FAB group C chemotherapy in children and adolescents with advanced stage (Bone Marrow \u00b1CNS) mature B-cell non-hodgkin lymphoma (B-NHL): a children's oncology group report. Blood. 2009; 114:Abstract 104.","journal-title":"Blood"},{"key":"e_1_3_1_77_1","volume-title":"Blood","author":"Goldman S","year":"2011","unstructured":"Goldman S, Galardy P, Smith L, The Efficacy of Rasburicase and Rituximab Combined with FAB Chemotherapy in Children and Adolescents with Newly Diagnosed Stage III\/IV, BMand CNS Mature B-NHL: A Children's Oncology Group Report. Blood, 2011;118:Abstract 2702."},{"key":"e_1_3_1_78_1","volume-title":"Leukemia","author":"Goldman S","year":"2012","unstructured":"Goldman S, Smith L, Anderson JR, Rituximab and FAB\/LMB 96 chemotherapy in children with Stage III\/IV B-cell non-Hodgkin lymphoma: a Children's Oncology Group report. Leukemia. 2012; doi: 10.1038\/leu.2012.255."},{"key":"e_1_3_1_79_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.21753"},{"key":"e_1_3_1_80_1","doi-asserted-by":"publisher","DOI":"10.1097\/MOP.0b013e3282f424b0"},{"key":"e_1_3_1_81_1","article-title":"Leveraging administrative data to monitor rituximab use in 2875 patients at 42 freestanding children's hospitals across the United States","author":"Kavcic M","year":"2012","unstructured":"Kavcic M, Fisher BT, Seif AE, Leveraging administrative data to monitor rituximab use in 2875 patients at 42 freestanding children's hospitals across the United States. J Pediatr. 2012; doi: 10.1016\/j.jpeds.2012.11.038.","journal-title":"J Pediatr"}],"container-title":["Pediatric Hematology and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.3109\/08880018.2013.783891","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T17:37:06Z","timestamp":1730741826000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.3109\/08880018.2013.783891"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4,9]]},"references-count":80,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["10.3109\/08880018.2013.783891"],"URL":"https:\/\/doi.org\/10.3109\/08880018.2013.783891","relation":{},"ISSN":["0888-0018","1521-0669"],"issn-type":[{"value":"0888-0018","type":"print"},{"value":"1521-0669","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,4,9]]}}}